Overview
Jerome Devy practices practicing medicine in Reims, France.
His clinical expertise encompasses Triple-Negative Breast Cancer, Delayed Growth, Melanoma, and Breast Cancer.
He is actively involved in clinical research, co-authoring 30 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jerome Devy
Is Jerome Devy a top-rated expert for Triple-Negative Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Jerome Devy is classified as an Experienced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jerome Devy participate in research or clinical trials?
Yes. Jerome Devy has published 30 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Jerome Devy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerMr. Devy isExperienced. Learn about Breast Cancer.
- Delayed GrowthMr. Devy isExperienced. Learn about Delayed Growth.
- MelanomaMr. Devy isExperienced. Learn about Melanoma.
- Triple-Negative Breast CancerMr. Devy isExperienced. Learn about Triple-Negative Breast Cancer.